Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paxlovid for Post-Exposure Prophylaxis of COVID-19 (EPIC-PEP)
NCT05047601Phase 3Completed
- Sponsor
- Pfizer
- Start
- Sep 2021
- Primary completion
- Apr 2022
- Modality
- Orthosteric Ligands
- Countries
- 17
01
Overview
A Phase 3 trial of Nirmatrelvir in coronavirus disease 2019 (COVID-19), sponsored by Pfizer. Started Sep 2021; status: completed.
02
Drugs
Nirmatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05047601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05047601.